AZN241227C75000
- 0.01
- 0.000.00%
AstraZeneca Newsroom
AstraZeneca PLC ADR Underperforms Tuesday When Compared To Competitors
Achilles Therapeutics Announces $12M AstraZeneca Deal, Plans Job Cuts
Express News | Achilles: Proprietary data, TRACERx samples, and material acquisition platforms will be transferred to AstraZeneca.
Achilles Therapeutics Sells TRACERx And MAP Assets To AstraZeneca For $12M, Transferring Tumor Data And Samples; Concludes Strategic Review With Plans For Workforce And Board Reductions
Press Release: Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca
London Shares Festive Ahead of Christmas Break; Vistry Slumps on Fresh Profit Warning
AstraZeneca, Daiichi Sankyo Withdraw EU Marketing Application for Lung Cancer Drug Candidate
AstraZeneca Pulls EU Marketing Application for Lung Cancer Treatment Amid Regulatory Feedback
AstraZeneca Withdraws EU Application for Datopotamab Deruxtecan in Lung Cancer
The USA FDA has revoked the emergency use authorization for four COVID-19 antibody drugs.
On December 24, Gelonghui reported that the USA Food and Drug Administration (FDA) has revoked the emergency use authorization for four COVID-19 antibody drugs, including Eli Lilly and Co's bebtelovimab, AstraZeneca's Evusheld, GlaxoSmithKline's sotrovimab, and Regeneron's REGEN-COV. The FDA stated in a letter earlier this month that the shelf life of these drugs has expired, and due to the spread of non-susceptible variants, they have not been authorized for patient use for more than a year. According to the FDA, the four companies mentioned above do not intend to continue providing the relevant products in the USA and will notify customers and suppliers.
Express News | US FDA: Revoked Emergency Use Authorization for AstraZeneca's Evusheld as of Dec 13 - Website
AstraZeneca PLC Stock Rises Monday, Underperforms Market
London Shares Rise; UK Economy Flatlines
Unusual Options Activity: COIN, AZN and Others Attract Market Bets, COIN V/OI Ratio Reaches 120.0
EST Dec 23rd Morning Delivery - In the last two hours of trading, 5 options with a high V/OI ratio were detected. With the market volatile, it's crucial to stay informed on the latest options trends.
AZN's Tagrisso Gets Approval in the EU for Expanded Use in NSCLC
AstraZeneca's Blockbuster Drug Tagrisso Wins EU Nod for Non-small Cell Lung Cancer
AstraZeneca Obtains EU Approval for Tagrisso in Non-small Cell Lung Cancer Treatment
AstraZeneca's Tagrisso Gains EU Approval for Unresectable EGFR-Mutated Lung Cancer
Why Astrazeneca (AZN) Outpaced the Stock Market Today
AstraZeneca Hits 4-week Low